Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: A multicenter retrospective study

Investigational New Drugs

Volumn 31, Issue 4, 2013, Pages 1035-1043

  Moscetti, Luca ^a,g   Nelli, Fabrizio ^a,g   Fabbri, Maria A ^a   Sperduti, Isabella ^b   Alesini, Daniele ^c   Cortesi, Enrico ^c   Gemma, Donatello ^d   Gamucci, Teresa ^d   Grande, Roberta ^e   Pavese, Ida ^e   Franco, Daniela ^f   Ruggeri, Enzo M ^a  

^a BELCOLLE HOSPITAL   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Department of Medical Oncology   (Italy)

^e FATEBENEFRATELLI HOSPITAL   (Italy)

^f ASL RMA   (Italy)

^g Outcome Research Network for Evaluation of Treatment Results in Oncology   (Italy)

Author keywords

Antiangiogenic therapy; Bevacizumab; Chemotherapy; Maintenance therapy; Metastatic colorectal cancer

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTERIAL THROMBOEMBOLISM; ARTICLE; BLEEDING DISORDER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART DISEASE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RETROSPECTIVE STUDY; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84880918721     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-9936-9     Document Type: Article

References (40)

1. Meyerhardt JA, Mayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352:476-487
2. Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8:579-591
3. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
4. Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with Oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544
5. Fuchs CS, Marshall J, Mitchell E et al (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25:4779-4786
6. Saltz LB et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013-2019
7. Hochster HS, Hart LL, Ramanathan RK et al (2008) Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 26:3523-3529
8. Meyerhardt JA, Li L, Sanoff HK et al (2012) Effectiveness of bevacizumab with first-line combination chemotherapy for medicare patients with stage IV colorectal cancer. J Clin Oncol 30:608-615
9. Jenab-Wolcott J, Giantonio BJ (2010) Antiangiogenic therapy in colorectal cancer: where are we 5 years later? Clin Colorectal Cancer 9(Suppl 1):S7-S15
10. Grothey A, Sugrue MM, Purdie DM et al (2008) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26:5326-5334
11. Van Cutsem E, Rivera F, Berry S et al (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20:1842-1847
12. Bennouna J, Sastre J, Arnold D et al (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomized phase 3 trial. Lancet Oncol 14:29-37
13. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
14. Kelsey JL, Whittemore AS et al (1996) Methods in observational epidemiology. Oxford University Press, New York
15. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
16. Tournigand C, Cervantes A, Figer A et al (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with Oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 24:394-400
17. Chibaudel B, Maindrault-Goebel F, Lledo G et al (2009) Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study. J Clin Oncol 27:5727-5733
18. Labianca R, Sobrero A, Isa L et al (2011) Italian Group for the Study of Gastrointestinal Cancer-GISCAD. Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. Ann Oncol 22:1236-1242
19. Gibson TB, Grothey A (2006) Do all patients with metastatic colorectal cancer need chemotherapy until disease progression? Clin Colorectal Cancer 6:196-201
20. Grothey A, Hart LL, Rowland KM, et al. (2008) Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial. J Clin Oncol. 26:(suppl; abstr 4010)
21. Wasan H, Adams RA, Wilson RH, et al. (2012) Intermittent chemotherapy (CT) plus continuous or intermittent cetuximab (C) in the first-line treatment of advanced colorectal cancer (aCRC): Results of the two-arm phase II randomized MRC COIN-b trial. J Clin Oncol 30: (suppl 4; abstr 536)
22. Pfeiffer P, Sorbye H, Qvortrup C, et al. (2012) Maintenance therapy with biweekly cetuximab (C) in the first-line treatment of metastatic colorectal cancer (mCRC): The NORDIC 7.5 study (NCT00660582), by the Nordic Colorectal Cancer Biomodulation Group. J Clin Oncol. 30:(suppl 4; abstr 3538).
23. Ebos JM, Lee CR, Cruz-Munoz W et al (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232-239
24. Loges S, Mazzone M, Hohensinner P, Carmeliet P (2009) Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 15:167-170
25. Mancuso MR, Davis R, Norberg SM et al (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116:2610-2621
26. Kopetz S, Hoff PM, Morris JS et al (2010) Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 28:453-459
27. Loupakis F, Cremolini C, Fioravanti A et al (2011) Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer 104:1262-1269
28. Cacheux W, Boisserie T, Staudacher L et al (2008) Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann Oncol 19:1659-1661
29. Miles D, Harbeck N, Escudier B et al (2011) Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol 29:83-88
30. Díaz-Rubio E, Gómez-España A, Massutí B et al (2012) First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist 17:15-25
31. Tournigand C, Samson B, Scheithauer W, et al. (2012) Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy and safety results of the International GERCOR DREAM phase III trial. J Clin Oncol. 30:(suppl 4; abstr LBA3500)
32. Yalcin S, Uslu R, Dane F, et al. (2012) Bevacizumab (BEV) plus capecitabine as maintenance therapy after initial treatment with BEV plus XELOX in previously untreated patients (pts) with metastatic colorectal cancer (mCRC): Mature data from STOP and GO, a phase III, randomized, multicenter study. J Clin Oncol. 30:(suppl 4; abstr 3565)
33. Piessevaux H, Buyse M, De Roock W et al (2009) Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial). Ann Oncol 20:1375-1382
34. Koda K, Ishida H, Katoh R, et al. (2012) Tumor shrinkage and overall survival (OS) from multicenter phase II study of modified FOLFOX7 (combination chemotherapy of infusional 5-FU/l-leucovorin and intermittent oxaliplatin) with bevacizumab in the first-line therapy of colorectal cancer: CRAFT trial. J Clin Oncol. 30 (suppl 4; abstr 616)
35. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300:2277-2285
36. Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10:559-568
37. Schutz FA, Je Y, Azzi GR, Nguyen PL, Choueiri TK (2011) Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol 22:1404-1412
38. Ranpura V, Hapani S, Wu S (2011) Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 305:487-494
39. Chong G, Tebbutt NC (2010) Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: balancing utility with low toxicity. Ther Adv Med Oncol 2:309-317
40. Schmoll HJ, Van Cutsem E, Stein A et al (2012) ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23:2479-2516